Miroslaw Brys

Miroslaw Brys

Company: Eli Lilly & Company

Job title: Senior Director, Neurodegeneration Clinical Head


SARM1 Inhibition as a Potential Therapeutic Strategy in ALS 12:00 pm

SARM1 is the central driver of axonal degeneration Genomics analysis suggest SARM1 as an ALS candidate risk gene Downstream effects of SARM1 inhibition might potentially translate to robust biomarker, electrophysiology and clinical efficacy signals in ALS trialRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.